Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
AssigneeUniversity of Connecticut
InventorsLinda H. Shapiro, Fernando A. Ferrer, Charan Devarakonda, James J. Grady
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for prognosing or diagnosing an obstructive renal dysfunction or ureteropelvic junction obstruction (UPJO) in a subject, involving detecting in a urine sample from a subject one or more proteins selected from the group consisting of Immunoglobulin superfamily containing leucine-rich repeat protein (ISLR); Nicotinate-nucleotide pyrophosphorylase [carboxylating] (QPRT); Prostaglandin reductase 1 (PTGR1); Vascular cell adhesion protein 1 (VCAM1); and Ficolin-2 (FCN2), or detectable portions thereof to identify the subject as at risk of or having an obstructive renal dysfunction or UPJO.
Claims11
A method for treating ureteropelvic junction obstruction (UPJO) in a subject, wherein the subject is a human child, comprising:
- (a) detecting in a urine sample from the subject one or more proteins selected from the group consisting of Immunoglobulin superfamily containing leucine-rich repeat protein (ISLR);
- Nicotinate-nucleotide pyrophosphorylase [carboxylating] (QPRT);
- Prostaglandin reductase 1 (PTGR1);
- Vascular cell adhesion protein 1 (VCAM1);
- and Ficolin-2 (FCN2);
- (b) comparing an amount of the one or more proteins in the urine sample to a standard;
- wherein the subject has an increase in the amount of at least one of the one or more proteins in the urine sample above the standard, diagnosing the subject as having UPJO;
- and
- (c) treating the subject with surgery, endopyelotomy, laparoscopic pyeloplasty, and/or placement of a stent.
A method for treating UPJO in a subject, comprising;
- (a) detecting one or more proteins selected from the group consisting of ISLR, QPRT, PTGR1, VCAM1, and FCN2, in a urine sample from a subject that has undergone treatment for the UPJO, wherein the subject is a human child;
- and
- (b) comparing an amount of the one or more proteins in the urine sample to a standard;
- wherein no change or an increase in the amount of the one or more proteins in the urine sample relative to the standard indicates the treatment was ineffective;
- and
- (c) modifying the treatment of the subject, wherein modifying the treatment comprises surgery, endopyelotomy, laparoscopic pyeloplasty, and/or placement of a stent.
Dependencies are inferred from the claim text.